Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 4, 2017. The report serves as a notification of the publication of a Base Prospectus approved by the UK Listing Authority on August 3, 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing regarding a debt program rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing announces the establishment of a £15,000,000,000 Euro Medium Term Note Programme involving GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GSK Capital K.K.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors related to operations. It includes a standard disclaimer stating that the Base Prospectus is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions without verifying eligibility.
Investor Verification Checklist
- Verify the full text of the Base Prospectus dated August 3, 2017, via the National Storage Mechanism (NSM) at www.morningstar.co.uk/uk/NSM.
- Confirm eligibility to access the prospectus based on country of residence as specified in the document.
- Review the terms of the £15 billion Euro Medium Term Note Programme for details on issuance conditions.